Top

Journal of Ovarian Research

Published in:

Open Access 01-12-2009 | Brief communication

Aberrant STYK1 expression in ovarian cancer tissues and cell lines

Authors: Kesmic A Jackson, Gabriela Oprea, Jeffrey Handy, K Sean Kimbro

Published in: Journal of Ovarian Research | Issue 1/2009

Abstract

Background

Overexpression of STYK1, a putative serine/threonine and tyrosine receptor protein kinase has been shown to confer tumorigenicity and metastatic potential to normal cells injected into nude mice. Mutation of a tyrosine residue in the catalytic STYK1 domain attenuates the tumorigenic potential of tumor cells in vivo, collectively, suggesting an oncogenic role for STYK1.

Methods

To investigate the role of STYK1 expression in ovarian cancer, a panel of normal, benign, and ovarian cancer tissues was evaluated for STYK1 immunoreactivity using STYK1 antibodies. In addition, mRNA levels were measured by reverse transcription PCR and real-time PCR of estrogen receptors, GPR30 and STYK1 following treatment of ovarian cell lines with estrogen or G1, a GPR30 agonist, as well as western analysis.

Results

Our data showed higher expression of STYK1 in cancer tissues versus normal or benign. Only normal or benign, and one cancer tissue were STYK1-negative. Moreover, benign and ovarian cancer cell lines expressed STYK1 as determined by RT-PCR. Estradiol treatment of these cells resulted in up- and down-regulation of STYK1 despite estrogen receptor status; whereas G-1, a GPR30-specific agonist, increased STYK1 mRNA levels higher than that of estradiol.

Conclusion

We conclude that STYK1 is expressed in ovarian cancer and is regulated by estrogen through a GPR30 hormone-signaling pathway, to the exclusion of estrogen receptor-alpha.

Available only for authorised users

Lingeman CH: Etiology of cancer of the human ovary: a review. J Natl Cancer Inst 1974, 53: 1603–1618.PubMed

Scott M, McCluggage WG, Hillan KJ, Hall PA, Russell SE: Altered patterns of transcription of the septin gene, SEPT9, in ovarian tumorigenesis. Int J Cancer 2006, 118: 1325–1329. 10.1002/ijc.21486PubMedCrossRef

Smith T, Stein KD, Mehta CC, Kaw C, Kepner JL, Buskirk T, Stafford J, Baker F: The rationale, design, and implementation of the American Cancer Society's studies of cancer survivors. Cancer 2007, 109: 1–12. 10.1002/cncr.22387PubMedCrossRef

Wu F, Safe S: Differential activation of wild-type estrogen receptor alpha and C-terminal deletion mutants by estrogens, antiestrogens and xenoestrogens in breast cancer cells. J Steroid Biochem Mol Biol 2007, 103: 1–9. 10.1016/j.jsbmb.2006.07.007PubMedCrossRef

Liu L, Yu XZ, Li TS, Song LX, Chen PL, Suo TL, Li YH, Wang SD, Chen Y, Ren YM, et al.: A novel protein tyrosine kinase NOK that shares homology with platelet- derived growth factor/fibroblast growth factor receptors induces tumorigenesis and metastasis in nude mice. Cancer Res 2004, 64: 3491–3499. 10.1158/0008-5472.CAN-03-2106PubMedCrossRef

Li YH, Zhong S, Rong ZL, Ren YM, Li ZY, Zhang SP, Chang Z, Liu L: The carboxyl terminal tyrosine 417 residue of NOK has an autoinhibitory effect on NOK-mediated signaling transductions. Biochem Biophys Res Commun 2007, 356: 444–449. 10.1016/j.bbrc.2007.02.154PubMedCrossRef

Ho SM: Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 2003, 1: 73. 10.1186/1477-7827-1-73PubMedCentralPubMedCrossRef

Syed V, Ulinski G, Mok SC, Ho SM: Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. J Natl Cancer Inst 2002, 94: 617–629.PubMedCrossRef

Chen Y, Li YH, Chen XP, Gong LM, Zhang SP, Chang ZJ, Zhang XF, Fu XY, Liu L: Point mutation at single tyrosine residue of novel oncogene NOK abrogates tumorigenesis in nude mice. Cancer Res 2005, 65: 10838–10846. 10.1158/0008-5472.CAN-05-1091PubMedCrossRef

10.

Kimbro KS, Duschene K, Willard M, Moore JA, Freeman S: A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment. Mol Biol Rep 2008, 35: 23–27. 10.1007/s11033-006-9047-1PubMedCrossRef

11.

Cunat S, Hoffmann P, Pujol P: Estrogens and epithelial ovarian cancer. Gynecol Oncol 2004, 94: 25–32. 10.1016/j.ygyno.2004.03.026PubMedCrossRef

12.

Roa BR, Slotman BJ: Action and counter-action of hormones in human ovarian cancer. Anticancer Res 1989, 9: 1005–1007.PubMed

13.

Backstrom T, Sanders D, Leask R, Davidson D, Warner P, Bancroft J: Mood, sexuality, hormones, and the menstrual cycle. II. Hormone levels and their relationship to the premenstrual syndrome. Psychosom Med 1983, 45: 503–507.PubMedCrossRef

14.

Mahlck CG, Backstrom T, Kjellgren O: Androstenedione production by malignant epithelial ovarian tumors. Gynecol Oncol 1986, 25: 217–222. 10.1016/0090-8258(86)90102-2PubMedCrossRef

15.

Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, Ando S, Maggiolini M: G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 2007, 67: 1859–1866. 10.1158/0008-5472.CAN-06-2909PubMedCrossRef

16.

Yalcin A: Quantification of thioredoxin mRNA expression in the rat hippocampus by real-time PCR following oxidative stress. Acta Biochim Pol 2004, 51: 1059–1065.PubMed

17.

Moriai R, Kobayashi D, Amachika T, Tsuji N, Watanabe N: Diagnostic relevance of overexpressed NOK mRNA in breast cancer. Anticancer Res 2006, 26: 4969–4973.PubMed

18.

Amachika T, Kobayashi D, Moriai R, Tsuji N, Watanabe N: Diagnostic relevance of overexpressed mRNA of novel oncogene with kinase-domain (NOK) in lung cancers. Lung Cancer 2007, 56: 337–340. 10.1016/j.lungcan.2007.01.002PubMedCrossRef

19.

Kondoh T, Kobayashi D, Tsuji N, Kuribayashi K, Watanabe N: Overexpression of serine threonine tyrosine kinase 1/novel oncogene with kinase domain mRNA in patients with acute leukemia. Exp Hematol 2009, 37: 824–830. 10.1016/j.exphem.2009.04.010PubMedCrossRef

20.

O'Donnell AJ, Macleod KG, Burns DJ, Smyth JF, Langdon SP: Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr Relat Cancer 2005, 12: 851–866. 10.1677/erc.1.01039PubMedCrossRef

21.

Otto C, Fuchs I, Kauselmann G, Kern H, Zevnik B, Andreasen P, Schwarz G, Altmann H, Klewer M, Schoor M, et al.: GPR30 does not mediate estrogenic responses in reproductive organs in mice. Biol Reprod 2009, 80: 34–41. 10.1095/biolreprod.108.071175PubMedCrossRef

22.

Funakoshi T, Yanai A, Shinoda K, Kawano MM, Mizukami Y: G protein-coupled receptor 30 is an estrogen receptor in the plasma membrane. Biochem Biophys Res Commun 2006, 346: 904–910. 10.1016/j.bbrc.2006.05.191PubMedCrossRef

Title: Aberrant STYK1 expression in ovarian cancer tissues and cell lines
Authors: Kesmic A Jackson
Gabriela Oprea
Jeffrey Handy
K Sean Kimbro
Publication date: 01-12-2009
Publisher: BioMed Central
Published in: Journal of Ovarian Research / Issue 1/2009
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/1757-2215-2-15

At a glance: The STEP trials

Springer Medicine

Aberrant STYK1 expression in ovarian cancer tissues and cell lines

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2009

Assessment of ultrasonographic features of polycystic ovaries is associated with modest levels of inter-observer agreement

Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies

Emerging role of microRNAs in diagnosis and treatment of various diseases including ovarian cancer

Thrombospondin-1 serum levels do not correlate with pelvic pain in patients with ovarian endometriosis

Positron emission tomography in ovarian cancer: 18F-deoxy-glucose and 16α-18F-fluoro-17β-estradiol PET

BMP-2 signaling in ovarian cancer and its association with poor prognosis